Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch

Pearson, Frances E., Muller, David A., Roalfe, Lucy, Zancolli, Marta, Goldblatt, David and Kendall, Mark A.F. (2015) Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. Vaccine, 33 48: 6675-6683. doi:10.1016/j.vaccine.2015.10.081


Author Pearson, Frances E.
Muller, David A.
Roalfe, Lucy
Zancolli, Marta
Goldblatt, David
Kendall, Mark A.F.
Title Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch
Journal name Vaccine   Check publisher's open access policy
ISSN 1873-2518
0264-410X
Publication date 2015-11-27
Year available 2015
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2015.10.081
Open Access Status Not yet assessed
Volume 33
Issue 48
Start page 6675
End page 6683
Total pages 9
Place of publication London, United Kingdom
Publisher Elsevier
Collection year 2016
Language eng
Abstract Adequate access to effective and affordable vaccines is essential for the prevention of mortality due to infectious disease. Pneumonia – a consequence of Streptococcus pneumoniae infection – is the world's leading cause of death in children aged under 5 years. The development of a needle-free, thermostable pneumococcal-conjugate vaccine (PCV) could revolutionise the field by reducing cold-chain and delivery constraints. Skin patches have been used to deliver a range of vaccines, with some inducing significantly higher vaccine-specific immunogenicity than needle-injected controls in pre-clinical models, though they have yet to be used to deliver a PCV. We dry-coated a licensed PCV onto a microprojection-based patch (the Nanopatch) and delivered it to mouse skin. We analysed resulting anti-polysaccharide IgG responses. With and without adjuvant, anti-polysaccharide IgG titres induced by Nanopatch immunisation were significantly higher than dose-matched intramuscular controls. These improved responses were primarily obtained against pneumococcal serotypes 4 and 14. Importantly, capsule-specific IgG correlated with functionality in an opsonophagocytic killing assay. We demonstrate enhanced anti-PCV immunogenicity when delivered by Nanopatch over intramuscular injection. As the first study of a PCV delivered by a skin vaccination technology, this report indicates the potential for reduced costs and greater global distribution of such a vaccine.
Keyword Skin vaccination
Polysaccharide
Pneumococcal-conjugate vaccine
Vaccine delivery
Microprojection
Opsonophagocytic killing assay
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 29 Dec 2015, 01:40:27 EST by System User on behalf of Scholarly Communication and Digitisation Service